Botox, Dysport and Xeomin are botulinum toxin type A medicines used to temporarily reduce selected muscle activity. In aesthetic care, this can soften dynamic lines created by repeated facial movement. They work through the same general pathway, but they are not identical products. Botox contains onabotulinumtoxinA, Dysport contains abobotulinumtoxinA, and Xeomin contains incobotulinumtoxinA. Health Canada lists each as a distinct prescription biologic product.
For patients, the most useful question is usually not “Which brand is best?” but “Which product and treatment plan fit this area, my anatomy, and my goals?” The clinic’s Wrinkle Softening & Neuromodulators page explains how this treatment category fits into individualized care.
What Botox, Dysport and Xeomin Have in Common
All three use botulinum toxin type A to reduce nerve signalling to targeted muscles. When a treated muscle contracts less strongly, movement-related lines can appear softer. This is different from filling a crease with volume or resurfacing the skin.
That distinction matters. Neuromodulators are generally most relevant when muscle movement contributes to a line or expression pattern. A line visible at rest may also reflect skin quality, collagen loss, sun exposure or volume change. The clinic’s Fine Lines and Wrinkles guide explains why several aging processes may exist at the same time.
Another important point is that their units are product-specific. A unit of one product cannot simply be treated as equivalent to a unit of another. Comparing treatment only by the number of units can therefore be misleading.
The Main Differences Between the Three
| Product | Active ingredient | What patients should understand |
|---|---|---|
| Botox Cosmetic | OnabotulinumtoxinA | A distinct formulation with its own dosing system |
| Dysport Aesthetic | AbobotulinumtoxinA | Uses a different formulation and product-specific potency units |
| Xeomin Cosmetic | IncobotulinumtoxinA | Another distinct formulation with product-specific dosing |
These differences do not create a simple ranking. Each product is made and tested through its own manufacturing process, formulation and potency assay. That is one reason fixed conversion ratios between brands should not be used as though the products were interchangeable.
The clinic’s Botox, Dysport, Xeomin and Nuceiva technology page provides more detail about the product family used within its injectable care.
Does One Work Faster or Last Longer?
Patients often hear that one neuromodulator “kicks in faster,” spreads more, or lasts longer. Those comparisons need context.
Outcomes are influenced by the treatment area, dose, injection pattern, muscle strength, anatomy, previous treatment and individual response. Studies can also be difficult to compare when they use different dosing approaches or endpoints.
For that reason, it is more responsible to discuss expected timing and duration for the specific product and plan being considered rather than promise that one brand will always act faster or last longer. The effect of botulinum toxin treatment is temporary, and muscle activity gradually returns.
Why Injection Technique Matters
The product is only one part of treatment. Placement, dose distribution and understanding of facial anatomy can strongly influence the result.
For example, forehead lines are produced by a muscle that also helps elevate the brows. Treating that area is not simply a matter of relaxing every visible line. The injector may consider brow position, forehead height, muscle strength and how nearby muscles interact. Patients interested in that area can review the clinic’s Forehead Lines information.
This is why two patients receiving the same brand may appropriately receive different plans. One may want subtle softening while another prefers greater movement reduction in a particular area. Product selection should sit inside that wider clinical decision.
Is a Higher Unit Number Stronger?
Not across brands.
Each manufacturer uses a product-specific method to define biological activity, so numerical units cannot be compared directly. Dysport may be discussed using a different number of units than Botox or Xeomin for a similar treatment objective, but that does not mean it is inherently stronger or weaker.
This matters when comparing quotes or previous treatments. A useful discussion should identify the exact product, area, goal and recommended plan rather than focus on the unit number alone.
Patients who want to understand the broader range of injectable and device options can also explore the clinic’s Technology Library.
What Creates a Natural-Looking Result?
A natural-looking result depends more on planning than on choosing a particular brand. Neuromodulators reduce selected muscle activity, but treatment does not have to eliminate all expression.
The appropriate degree of movement reduction depends on anatomy and preferences. Some people want softer movement while maintaining substantial expression. Others may prefer greater reduction in a particular area. If a crease remains visible at rest, skin-focused treatment may sometimes be considered separately rather than simply adding more neuromodulator.
Risks and Limitations
Botulinum toxin injections are medical treatments. Temporary injection-site discomfort, bruising or headache can occur. Unwanted weakness in nearby muscles may also cause effects such as asymmetry or eyelid or brow changes, depending on the area treated. Product monographs contain additional warnings and precautions clinicians must consider.
Risk assessment depends on the person’s health history, treatment area and planned approach. A consultation is therefore the right place to review individual suitability rather than choosing a product from an online comparison alone.
Frequently Asked Questions
Is Botox better than Dysport or Xeomin?
There is no universal winner. The appropriate choice depends on the treatment area, clinician assessment, previous response, goals and the characteristics of the individual product.
Can I switch brands?
A clinician may consider another botulinum toxin product in a future plan. Because the products are not dose-equivalent, switching requires a fresh dosing decision rather than copying the previous unit number.
Are all three used for the same areas?
There is overlap, but approved indications and clinical use are product-specific. The product and treatment area should be discussed with the treating clinician.
Should price per unit determine my choice?
Not by itself. Since units are not interchangeable, price per unit across different brands is not a direct comparison of treatment strength or total value.
Choosing Between Botox, Dysport and Xeomin
Botox, Dysport and Xeomin share the same broad treatment principle, but they are distinct medicines. Their active ingredient names, formulations and unit systems differ, and treatment numbers cannot be compared one-to-one across brands.
A useful consultation focuses on facial movement, anatomy, goals, previous experience and the specific area being treated. If you are considering neuromodulators, the clinic’s consultation page can help you discuss the options and understand why a particular product may be recommended for your plan.